BioTuesdays

Category - Markets

Anavex
Markets

Maxim ups Anavex Life Sciences PT to $7

Maxim Group raised its price target for Anavex Life Sciences (NASDAQ:AVXL) to $7 from $5, after factoring in Anavex 2-73 for additional indications: Rett syndrome and Parkinson’s disease, beyond Alzheimer’s disease. The...

May 16, 2018
Markets

Roth starts Daré Bioscience at buy; PT $6

Roth Capital Partners initiated coverage of Daré Bioscience (NASDAQ:DARE) with a “buy” rating and $6 price target. The stock closed at $1.07 on May 15. Daré brings innovation to the contraception market, writes analyst...

May 16, 2018
Sophiris Bio Logo
Markets

Maxim ups Sophiris Bio PT to $8

Maxim Group raised its price target for Sophiris Bio (NASDAQ:SPHS) to $8 from $5, factoring in topsalysin data in prostate cancer at the end of the second quarter. The stock was quoted at $3.55 in afternoon trading on...

May 15, 2018
Zymeworks Logo
Markets

Ladenburg starts Zymeworks at buy; PT $25

Ladenburg Thalmann initiated coverage of Zymeworks (NYSE:ZYME) with a “buy” rating and $25 price target. The stock closed at $15.84 on May 14. Zymeworks is developing bispecific/multifunctional biotherapeutics initially...

May 15, 2018
Coherus BioSciences Logo
Markets

Maxim ups Coherus Biosciences PT to $22

Maxim Group raised its price target for Coherus Biosciences (NASDAQ:CHRS) to $22 from $18 after the FDA has accepted for review the recently resubmitted BLA for CHS-1701 (Neulasta biosimilar). This is a Type I response...

May 14, 2018
Tandem Diabetes Care
Markets

Piper ups Tandem Diabetes to OW; PT $13

Piper Jaffray upgraded Tandem Diabetes (NASDAQ:TNDM) to “overweight” from “neutral” and raised its price target to $13 from $8 after hosting meetings with the company’s CEO and CFO. The stock closed at $8.90 on April 11...

May 14, 2018
Proteon Therapeutics
Markets

HCW ups Proteon Therapeutics to buy; PT $3

H.C. Wainwright upgraded Proteon Therapeutics (NASDAQ:PRTO) to “buy” from “neutral” and raised its price target to $3 from $2.30. “While investors may have written Proteon off after the failure of the PATENCY-1 study in...

May 10, 2018
TransEnterix
Markets

BTIG ups TransEnterix to buy; PT $3.50

BTIG upgraded TransEnterix (NASDAQ:TRXC) to “buy” with a price target of $3.50 after the company posted first quarter revenue above expectations. The stock closed at $1.83 on April 8. Dr. Sean Lavin writes that there...

May 9, 2018
IntelGenx Logo
Markets

IntelGenx closes private placement financing

IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) closed a private placement of 320 units at a price of $10,000 (U.S.) a unit for gross proceeds of $3.2-million. Proceeds will be used for the company’s Montelukast Phase 2a...

May 9, 2018